Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Jun 2, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Melanoma

Phase Ib Trial Shows 40 Percent
of Patients Receiving Keytruda Alive
After 36-Month Follow Up

 

Long-term follow-up from a phase Ib trial in newly diagnosed and previously treated patients with advanced melanoma showed that 40 percent of patients were alive three years after starting Keytruda (pembrolizumab), with similar 36-month overall survival rates in both groups.

The study, KEYNOTE-001, will be presented at the annual meeting of the American Society of Clinical Oncology.

Keytruda received accelerated approval from FDA in September 2014 for the treatment of advanced melanoma, based on data from KEYNOTE-001. Additional clinical studies, KEYNOTE-002 and KEYNOTE-006, have also shown a survival benefit with Keytruda in patients with advanced melanoma when compared with chemotherapy or Yervoy (ipilimumab), according to ASCO. Keytruda, a PD-1 inhibitor, is sponsored by Merck, which funded KEYNOTE-001.



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter